Mission Statement, Vision, & Core Values (2026) of Porton Pharma Solutions Ltd.

Founded in 2005, Porton Pharma Solutions Ltd. has grown into a global CDMO powerhouse with more than 5,300 employees and R&D and manufacturing sites across China, the United States, Belgium, Switzerland, Denmark and Slovenia, delivering on a mission of "enabling the public's early access to good medicines" through a portfolio that spans small molecules, biologics and gene and cell therapies and a proven track record of over 4,600 milestone projects for more than 1,300 international clients; driven by a vision to be "the most open, innovative and reliable pharmaceutical service platform in the world," Porton combines state-of-the-art facilities, adherence to global regulatory standards and a values-led culture-Customer First, Efficient Execution, Pursuit of Excellence, Embrace Changes and Teamwork-while embedding sustainability into strategy with announced 2030 targets to advance green development and accelerate timely patient access to high-quality medicines

Porton Pharma Solutions Ltd. (300363.SZ) - Intro

• Founded: 2005
• Headquarters: Chongqing, China
• Employees: >5,300
• Completed projects: >4,600 milestone projects
• Global clients: >1,300
• Therapy areas: Small molecules, biologics, gene & cell therapies

• Deliver high-quality, regulatory-compliant development and manufacturing solutions that accelerate client drug programs from concept to commercialization.
• Enable global access to advanced therapeutics by integrating scientific innovation with scalable manufacturing.

• To be a leading global partner for pharmaceutical innovation, recognized for technical excellence, regulatory reliability and timely delivery across complex modalities.
• To expand capabilities that anticipate the evolving needs of biologics, cell & gene therapies and next-generation small-molecule platforms.

• Quality & Compliance - adherence to international GMP, GLP and regulatory expectations across jurisdictions.
• Client-centricity - flexible, collaborative project management tailored to partner timelines and risk profiles.
• Innovation - continual investment in R&D and platform technologies to support novel modalities and process intensification.
• Integrity & Transparency - ethical conduct in data, documentation and supply-chain practices.
• Global Collaboration - cross-border teams and facilities that de-risk programs through geographic diversification.

• Capacity expansion in biologics and ATMP manufacturing to meet rising global demand for cell & gene therapies.
• Strengthening regulatory alignment across China, EU and US markets to shorten approval timelines for clients.
• Investing in digital manufacturing and analytics to improve batch release speed, traceability and cost-efficiency.
• Deepening partnerships with biotech and pharma customers to convert early-stage discovery programs into commercial supply agreements.

Porton Pharma Solutions Ltd. (300363.SZ) - Overview

• Mission emphasis: expedite patient access to safe, effective medicines through integrated CDMO/CRO services and regulatory support.
• Core strategic aim: transparency, innovation and reliability across the value chain-from API development to commercial-scale manufacturing.
• Customer-centric delivery: tailored solutions for global biopharma partners, prioritizing speed-to-clinic and regulatory readiness.

• Commitment to continuous improvement: iterative enhancement of process development, analytical capabilities and quality systems to reduce time-to-market.
• Sustainability alignment: announced 2030 targets to reduce environmental footprint while scaling capacity for biologics and small molecule production.

• Operational priorities tied to the mission:
  • Accelerate IND-enabling studies and GMP batches to reduce clinic-start timelines by targeted percentages.
  • Expand high-margin services (process development, biologics CMC) to diversify revenue and shorten partner timelines.

• How mission translates into measurable outcomes:
  • Shorter cycle times: internal goals to cut development-to-GMP timelines by double-digit percentages versus prior baselines.
  • Quality & compliance: sustain regulatory inspection readiness across export and domestic markets to minimize market-entry delays.
  • Sustainability metrics: reduce energy intensity and waste generation per unit produced by 2030 (company-published targets).

Porton Pharma Solutions Ltd. (300363.SZ) - Mission Statement

• Accelerate public access to high-quality medicines by shortening development timelines and expanding global service coverage.
• Maintain openness and transparency across R&D, manufacturing and regulatory support, ensuring traceability and client visibility at every stage.
• Drive continuous innovation in platform capabilities-analytical, clinical, CMC and regulatory-so partners can de-risk development and scale efficiently.
• Operate responsibly: embed environmental management, occupational safety and supply-chain integrity into core operations.
• Create measurable value for shareholders through sustainable revenue growth, disciplined margin expansion and targeted R&D investments.

• Service Integration - combine discovery services, CMC, analytical testing, clinical supply and regulatory affairs into end-to-end solutions.
• Open Collaboration - data-sharing platforms, client portals and cross-border partnerships to improve transparency and shorten cycle times.
• Innovation Investment - prioritize platform upgrades, AI-enabled analytical workflows and biologics process development.
• Sustainability & Compliance - implement certified environmental management systems and supplier audits to meet global standards.

• Reduce average development turnaround for CMC deliverables by 25% within three years through process standardization and digital tools.
• Increase high-margin integrated service revenue to represent >40% of total topline within 36 months.
• Allocate at least 8-12% of annual revenue to platform R&D and capital upgrades to sustain innovation.
• Achieve third-party environmental certification (e.g., ISO 14001) across 100% of core manufacturing sites within two years.

Porton Pharma Solutions Ltd. (300363.SZ) - Vision Statement

• Customer First - proactively understanding and exceeding customer needs through integrated service offerings, rapid project turnarounds and tailored technical solutions.
• Efficient Execution - decisive, transparent discussions followed by unconditional execution to ensure on-time delivery and high project predictability.
• Pursuit of Excellence - continuous learning, data-driven process improvement and receptive feedback loops to raise quality and shorten development cycles.
• Embrace Changes - fostering an innovation culture that pilots new technologies, digital workflows and flexible manufacturing to adapt to market shifts.
• Teamwork - sincerity, professionalism and cross-disciplinary trust to accelerate problem-solving and increase throughput.
• Sustainable Development - aligning business growth with environmental targets and social responsibility through quantified 2030 sustainability goals.

• Customer-centric R&D partnerships: convert customer needs into scalable processes within agreed timelines and cost targets.
• Operational excellence initiatives: reduce cycle-time variability and increase plant utilization through lean and digital programs.
• Sustainability integration: embed energy, emissions and waste KPIs into capital projects and service contracts.
• Talent and culture: invest in cross-functional training, open feedback mechanisms and incentive structures aligned with execution and collaboration.

• 50% reduction in Scope 1 & Scope 2 greenhouse gas emissions vs. 2023 baseline.
• Increase renewable energy share to 30% of total site energy consumption.
• Reduce hazardous waste generation by 40% and overall waste intensity by 30% per revenue unit.
• Improve water use efficiency: 25% reduction in water intensity per unit of production.
• Achieve ISO 14001 coverage across all major manufacturing sites and incorporate circular design principles in new builds.

• Customer First → Net promoter score (NPS) targets: ≥65 for key accounts; contract renewal rate ≥85%.
• Efficient Execution → Project on-time delivery rate ≥92%; average cycle-time reduction 20% by 2026.
• Pursuit of Excellence → Defect per million opportunities (DPMO) reduction target of 60% vs. 2023.
• Embrace Changes → 25% of CAPEX allocated to digital and green process upgrades by 2027.
• Teamwork → Employee engagement score ≥80; internal cross-functional project participation ≥30% of workforce.

• Consistent revenue growth with expanding gross margins driven by higher-value CDMO projects.
• R&D intensity rising toward the 10% target, indicating stronger pipeline development and technical differentiation.
• Improving plant utilization and reduced cycle times reflecting Efficient Execution and teamwork.
• Quarterly reporting on emissions, renewable energy adoption and waste intensity against the 2030 roadmap.
• Customer retention and NPS metrics showing traction of the Customer First approach.